HOME >> MEDICINE >> NEWS
Highest sustained virologic response in treatment of Hepatitis C ever reported in prospective study

A combination treatment of Pegasys (peginterferon alfa-2a 40kd) a pegylated interferon, with ribavirin, an orally active anti-viral medication, has shown some of the most effective treatment rates yet for individuals with hepatitis C. The combination treatment yielded a 61 percent sustained virologic response (SVR), the highest SVR ever reported in a prospective trial for a pegylated interferon using an intent-to-treat (ITT) analysis, according to Dr. Donald Jensen at Rush-Presbyterian-St. Luke's Medical Center.

SVR refers to a patient's continued undetectable serum hepatitis C (HCV) RNA levels six months after discontinuation of treatment. Results of a recently completed phase III study of the investigational hepatitis C therapy were presented today at the European Association for the Study of Liver (EASL) annual meeting in Madrid, Spain.

The study also revealed strong evidence that, to achieve optimal results, treatment regimens should be based on hepatitis C virus genotype, rather than on the traditional, weight-based methodology.

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis and liver cancer. It is also the primary reason for liver transplantation in the United States. An estimated 2.7 million Americans are chronically infected with the virus, with about 35,000 new infections reported each year.

"These results are unprecedented," explained Jensen, a U.S. investigator in the trial and director of Hepatology at Rush-Presbyterian St. Luke's Medical Center, Chicago. "Physicians can confidently expect that when Pegasys is available they can prescribe it for the most appropriate length and dose of combination treatment based on a patient's genotype and achieve optimal results." Rush-Presbyterian St. Luke's Medical Center was one of 29 U.S. trial locations.

The study also found a 51 percent SVR, the highest ever achieved, for patients with genotype 1, the most difficu
'"/>

Contact: John M. Pontarelli
jpontare@rsh.net
312-942-5949
Rush University Medical Center
18-Apr-2002


Page: 1 2 3

Related medicine news :

1. Highest average rate of US road deaths on Independence Day
2. Highest known catalytic rate for superoxide dismutation achieved
3. Patients May Not Be Receiving The Highest Quality Of Care
4. Acute Urinary Retention And BPH-Related Surgery: Predicting Those At Highest Risk And Prevention With Finasteride
5. Chemical Societys Highest Award Goes To Ronald Breslow
6. The sustained benefits of very early treatment of rheumatoid arthritis with anti-TNF-alpha therapy
7. Non-drug treatment device delivers sustained blood pressure reductions within 3-4 weeks in the home
8. New study demonstrates significant and sustained improvements in BPH symptoms with AVODART ™
9. Children achieve sustained ADHD symptom improvement with long-term, once-daily use of Adderall XR
10. New data show fast and significant weight loss with Xenical sustained over time
11. New data shows rapid and sustained weight loss with Xenical

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a ... Miami, and Raleigh regions, is organizing an extended charity drive to benefit the ... chromosome abnormality. , After struggling since birth with several health challenges, T.J. was ...
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their approach ... patient is doing more than filling out a survey; in many cases health professionals ... emphasis in health care and research on the importance of active engagement with patients ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
Cached News: